Table 1.

Baseline characteristics of organ recipients and donors

ATGDaclizumab
Characteristicsn = 113n = 114
Males, n (%)52 (46.0)59 (51.8)
Age, yr (mean ± SD)45.4 ± 10.346.9 ± 9.0
Cause of ESRD, n (%)
    Glomerulonephritis51 (45.2)45 (39.4)
    Uropathy11 (9.7)15 (13.2)
    Autosomal dominant polycystic kidney disease10 (8.9)10 (8.8)
    Diabetes4 (3.5)2 (1.7)
    Other26 (23.0)25 (21.9)
    Unknown11 (9.7)17 (15.0)
Number of HLA mismatches
    HLA A0.9 ± 0.70.9 ± 0.7
    HLA B1.1 ± 0.71.1 ± 0.8
    HLA DR0.9 ± 0.70.9 ± 0.8
First graft, n (%):30 (26.5%)34 (29.8%)
    Current PRA (mean ± SD, %)35 ± 3239 ± 33
    Peak PRA (mean ± SD, %)77 ± 2079 ± 20
Second graft, n (%):59 (52.2%)58 (50.9%)
    Current PRA (mean ± SD, %)35 ± 2939 ± 31
    Peak PRA (mean ± SD, %)69 ± 2375 ± 18
Third and fourth graft, n (%):24 (21.2%)22 (19.3%)
    Current PRA (mean ± SD, %)26 ± 3027 ± 31
    Peak PRA (mean ± SD, %)60 ± 3061 ± 27
All patientsn = 113n = 114
    Current PRA (mean ± SD, %)33 ± 3037 ± 32
    Peak PRA (mean ± SD, %)69 ± 2574 ± 22
    % with PRA >80%8.8%11.4%
Cold ischemia time, h (mean ± SD)24.0 ± 7.922.7 ± 6.8
Donor
    Males, n (%)76 (67.3)65 (57.0)
    Age, yr (mean ± SD)44.3 ± 13.844.6 ± 14.8
    Death from stroke, n (%)56 (49.6)46 (40.4)
Cytomegalovirus serologic status, n (%)
    D+R+37 (32.7)45 (39.5)
    D+R−16 (14.2)12 (10.5)
    D−R+46 (40.7)42 (36.8)
    D−R−14 (12.4)15 (13.2)